Uptake of COVID-19 Booster Dose Among Saudi Arabian Population
Overview
Authors
Affiliations
: Although several vaccines have been produced and administered around the world, new SARS-CoV-2 worsened the COVID-19 infection risk and impacted the initial vaccine dosage effectiveness. Based on studies indicating that the third and fourth COVID-19 vaccine doses significantly reduced COVID-19 transmission, Saudi Arabia has been administering COVID-19 booster vaccine doses to its citizens. The purpose of this study was to evaluate the uptake of the COVID-19 vaccine booster in relation to the socio-demographic characteristics and other associated factors among the Saudi population. : This study was an online analytical cross-sectional study using a self-administered questionnaire. Pearson Chi-square test and multiple logistic regression analyses were used to determine factors associated with the uptake of COVID-19 booster dose vaccines. : A total of 2332 responded to our study. Overall, 527 (22.6%) participants had received a booster dose. An age of 55 and above (aOR: 5.415; 95% CI: 2.719-10.783), Eastern region (aOR: 2.513; 95% CI: 1.566-4.033), history of influenza vaccination at annual intervals (aOR: 2.387; 95% CI: 1.730-3.293), the first dose of Moderna vaccine (aOR: 1.324; 95% CI: 1.160-1.510), and cancer (aOR: 2.161; 95% CI: 1.218-3.879) were independent factors most associated with a higher uptake of the COVID-19 vaccine booster dose. In contrast, the second dose of Moderna vaccine (aOR: 0.794; 95% CI: 0.683-0.922), AstraZeneca vaccine (aOR: 0.691; 95% CI: 0.509-0.939), strong symptoms from side effects after the second dose of the COVID-19 vaccine (aOR: 0.615; 95% CI: 0.404-0.935) were independent factors most associated with a lower uptake of the COVID-19 vaccine booster dose. : Our findings indicate low COVID-19 vaccine booster uptake. This necessitates the need for strategies to address discouraging factors of the COVID-19 vaccine booster dose uptake and engage the Saudi population to raise awareness about the importance of the booster dose.
Gauna F, Raude J, Khouri C, Cracowski J, Ward J Hum Vaccin Immunother. 2025; 21(1):2471225.
PMID: 40058398 PMC: 11901385. DOI: 10.1080/21645515.2025.2471225.
Kitro A, Sirikul W, Polpitakchai C, Panumasvivat J, Yamsiri R, Tasena P Vaccines (Basel). 2025; 12(12.
PMID: 39772043 PMC: 11680416. DOI: 10.3390/vaccines12121381.
Paridans M, Monseur J, Gillain N, Husson E, Darcis G, Saegerman C PLOS Glob Public Health. 2024; 4(12):e0004066.
PMID: 39700212 PMC: 11658518. DOI: 10.1371/journal.pgph.0004066.
Alrasheedy A, Alharbi A, Alturaifi H, Alkhamis R, Almazyad R, Almozaini S Hum Vaccin Immunother. 2024; 20(1):2414551.
PMID: 39693183 PMC: 11487963. DOI: 10.1080/21645515.2024.2414551.
Nath Roy D, Ferdiousi N, Hossen M, Islam E, Azam M Vaccine X. 2024; 18:100480.
PMID: 38585380 PMC: 10997838. DOI: 10.1016/j.jvacx.2024.100480.